Table 1. Baseline characteristics according to the use of targeted therapies.
| Total (n = 108) |
Pre-PEA targeted therapy (n = 35) | Pre-PEA supportive therapy (n = 73) | P Value | |
|---|---|---|---|---|
| Male gender | 37 (34.3%) | 9 (25.7%) | 28 (38.4%) | 0.076 |
| Age (years) | 46.2 ± 15.2 | 44.1 ± 14.1 | 47.1 ± 15.7 | 0.333 |
| NYHA Functional Class | 0.020 | |||
| I | 6 (5.9%) | 3 (9.2%) | 3 (4.4%) | |
| II | 41 (40.2%) | 8 (24.2%) | 33 (47.8%) | |
| III | 34 (33.3%) | 11 (33.3%) | 23 (33.3%) | |
| IV | 21 (20.6%) | 11 (33.3%) | 10 (14.5%) | |
| Hemodynamics | ||||
| RAP (mmHg) | 13.0 ± 6.2 | 13.3 ± 6.4 | 12.8 ± 6.8 | 0.679 |
| mPAP (mmHg) | 50.8 ± 13.0 | 54.3 ± 13.7 | 49.0 ± 12.4 | 0.048 |
| PAOP (mmHg) | 14.6 ± 5.9 | 14.7 ± 6.1 | 14.6 ± 5.9 | 0.916 |
| CO (L/min) | 3.9 ± 1.3 | 3.4 ± 0.9 | 4.1 ± 1.4 | 0.003 |
| PVR (WU) | 10.5 ± 5.5 | 12.5 ± 6.2 | 9.4 ± 4.7 | 0.110 |
| BNP (pg/dL) | 268.5 ± 283.2 | 284.3 ± 211.9 | 260.5 ± 314.4 | 0.687 |
| 6MWD (m) | 365.9 ± 109.6 | 352.8 ± 106.8 | 373.0 ± 111.8 | 0.492 |